Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

GlobeNewsWire

25 Jun 2026, 00:28 UTC · 2h ago

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

What the story claims

3 claims · each scored for market impact

What matters in this story

1
GRAIL's NHS-Galleri Trial failed to achieve its primary endpoint regarding the reduction of late-stage cancer diagnoses. — The failure of a primary clinical trial endpoint is a fundamental blow to the company's core product value and commercial viability.
-0.90
2
GRAIL is facing a securities class action lawsuit alleging it misled investors regarding the trial design and the likelihood of success. — Legal liabilities and fraud allegations create additional financial risk and reputational damage beyond the trial failure.
-0.40
3
GRAIL management admitted that the three-year follow-up period for the trial was likely insufficient. — This admission suggests a potential failure in trial design or management oversight, casting doubt on current operational competence.
-0.30

Which stocks this story touches

6 related stories

GlobeNewsWire
2h ago
Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman
- class action
- clinical trial
- litigation
Read

GRAIL, Inc. (GRAL) Faces… — EMBC -1.00 | NewsImpactScreener

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

What matters in this story

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

What matters in this story

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

NASDAQ: ENSG Investigation: Kessler Topaz Meltzer & Check, LLP Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Investors to Contact the Firm

Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business – Hagens Berman

GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman

Via Transportation, Inc. Securities Class Action Result of Undisclosed Growth Obstacles and approximately 70% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Activision Blizzard, Inc. Notice of June 30, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

What matters in this story

Next reads from the same story arc

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

What matters in this story

Next reads from the same story arc

Erasca, Inc. (ERAS) Faces Securities Class Action Amid Patient Death, Intellectual Property Questions, $2.8 Billion Market Cap Loss – Hagens Berman

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

NASDAQ: ENSG Investigation: Kessler Topaz Meltzer & Check, LLP Encourages The Ensign Group, Inc. (NASDAQ: ENSG) Investors to Contact the Firm

Embecta Corp. (EMBC) Faces Securities Class Action for Allegedly Concealing Competitive Threats to Pen Needle Business – Hagens Berman

GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition – Hagens Berman

Via Transportation, Inc. Securities Class Action Result of Undisclosed Growth Obstacles and approximately 70% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Activision Blizzard, Inc. Notice of June 30, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline